YP
AQST icon

YANKCOM Partnership’s Aquestive Therapeutics AQST Stock Holding History

YANKCOM Partnership’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-600
Closed -$2.49K – 314
2026
Q1 		$2.49K Hold
600
– – ﹤0.01% 326
2025
Q4 		$3.88K Buy
+600
New +$3.74K ﹤0.01% 319

Other funds holding AQST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
EAM
Everstar Asset Management Mooresville, North Carolina $207M AUM 18.14% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

YANKCOM Partnership's AQST Position: Q2 2026 in Review

YANKCOM Partnership sold out of Aquestive Therapeutics (AQST) in Q2 2026, closing a stake of 600 shares — an estimated $2.49K sold.

YANKCOM Partnership first reported a position in AQST in Q4 2025 and held it in 2 quarters. The position peaked at $3.88K in Q4 2025. 67 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • YANKCOM Partnership reported no remaining Aquestive Therapeutics position as of Q2 2026 after selling out during the quarter.
  • YANKCOM Partnership sold 600 Aquestive Therapeutics shares in Q2 2026, an estimated $2.49K.
  • YANKCOM Partnership first reported a position in Aquestive Therapeutics in Q4 2025 and held it in 2 quarters.
  • YANKCOM Partnership's Aquestive Therapeutics position peaked at $3.88K in Q4 2025.
  • 67 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on YANKCOM Partnership's 13F filing for Q2 2026, filed 21 Jul 2026.